Diabetes drug boost chemo potency

Wed, 09 May 2007
According to experts at the Dana-Farber Cancer Institute, a diabetes drug in common use could dramatically boost how effective a platinum-base cancer drug is. Conducting experiments involving mice, the research team combined diabetic medication rosiglitazone with a platinum chemotherapy agent, to startling results.

The scientists found that the dual drugs reduced mouse tumours as much as three times more effectively than either of the individual drugs. Results of the study were published in the article Cancer Cell.

Depending on its efficiency amongst humans, the combo drug could have a role to play in the treatment of ovarian, lung and other cancers. Bruce Speigelman, the senior author, reportedly commented: "There's still a huge gulf between these experiments and human cancers. But it's worked in every animal model of cancer we’ve looked at, and I think there’s a fair chance it will help people."
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.